Skip to main content
SpringerLink
Log in

Entwicklung von neuen topischen Substanzen zur Therapie der atopischen Dermatitis

Development of new topical substances for the treatment of atopic dermatitis

  • Leitthema
  • Published:
Die Dermatologie Aims and scope Submit manuscript

This article has been updated

Zusammenfassung

Die atopische Dermatitis (AD) gehört zu den häufigsten chronisch entzündlichen Hauterkrankungen. Im klinischen Alltag zeigen ca. 80 % der Patient:innen eine leichte bis mittelschwere Ausprägung, die in der Regel mit einer topischen Therapie versorgt wird. Die topische antientzündliche Therapie bildet somit weiterhin neben der Basistherapie den Therapiestandard. Es stehen mit den topischen Glukokortikosteroiden (TGC) und topischen Calcineurininhibitoren (TCI) 2 potente zugelassene Substanzklassen zur Verfügung. Neben neu entwickelten Systemtherapien für die moderate bis schwere AD gibt es auch neue Therapieansätze bei der topischen antientzündlichen Behandlung. Topische Januskinase(JAK)-Inhibitoren zeigen einen sehr guten therapeutischen Effekt. Zur topischen Applikation sind aus dieser Substanzgruppe bislang jedoch nur Delgocitinib in Japan und seit Ende 2021 auch Ruxolitinib in den USA zugelassen. Mit Crisaborol gibt es einen, ebenfalls in den USA zugelassenen Phosphodiesterase-4-Inhibitor, weitere Substanzen mit diesem Wirkprinzip werden derzeit untersucht. Interessante Ergebnisse weiterer klinischer Studien lassen auf neue Substanzen und Therapieansätze hoffen.

Abstract

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. In everyday clinical practice, about 80% of patients present with mild to moderate disease, which is usually treated with topical therapy. Topical anti-inflammatory therapy thus continues to be the standard of care in addition to the basic therapy. Topical glucocorticoids (TGC) and topical calcineurin inhibitors (TCI) are two potent approved substances that are available. In addition to newly developed systemic therapies for moderate to severe AD, there are also new therapeutic approaches in anti-inflammatory topical treatment. Topical Janus kinase inhibitors show a high therapeutic effect. However, only delgocitinib and ruxolitinib have so far been approved for topical administration in Japan and the USA since 2021. Crisaborole, a phosphodiesterase 4 inhibitor, also received approval in the USA. Other phosphodiesterase inhibitors are currently being investigated in clinical trials. Interesting results of clinical studies give hope for further substances and therapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 24 May 2022

    In diesem Artikel wurden falsche Angaben zum Zeitschriftennamen und den ISSNs gemacht. Dies wurde korrigiert.

Literatur

  1. Zietze HA, Cabral C, Theobald K et al (2021) Epidemiologie und Therapie von erwachsenen Patienten mit atopischer Dermatitis. Hautarzt 72(11):963–974

    Article  Google Scholar 

  2. Traidl S, Werfel T, Traidl-Hoffmann C (2022) Atopic Eczema: Pathophysiological Findings as the Beginning of a New Era of Therapeutic Options. Handb Exp Pharmacol 268:101–115. https://doi.org/10.1007/164_2021_492. PMID: 34236520

    Article  PubMed  Google Scholar 

  3. Werfel T, Allam JP, Biedermann T et al (2016) Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 138(2):336–349

    Article  CAS  Google Scholar 

  4. Suárez-Fariñas M, Dhinra N, Gittler J et al (2013) Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol 132(2):361–370

    Article  Google Scholar 

  5. Traidl S, Heratizadeh A, Werfel T, Dressler C (2021) Online survey to identify current challenges in atopic dermatitis management and guideline implementation in German-speaking countries. Eur J Dermatol 31(6):806–812

    Article  Google Scholar 

  6. Werfel T, Heratizadeh A, Aberer W et al (2016) S2k guideline on diagnosis and treatment of atopic dermatitis. J Dtsch Dermatol Ges 14(1):92–106

    PubMed  Google Scholar 

  7. Abeck D (2014) Dermatologische Therapie mit topischen Glukokortikoiden: aktueller Stand und zukünftige therapeutische Entwicklungen. Akt Dermatol 40(01/02):38–40

    Google Scholar 

  8. Axon E, Chalmer JR, Santer M et al (2021) Safety of topical corticosteroids in atopic eczema: an umbrella review. BMJ Open 11(7):e46476

    Article  Google Scholar 

  9. Aschoff R, Lang A, Koch E (2022) Effects of intermittent treatment with topical corticosteroids and calcineurin inhibitors on epidermal and dermal thickness using optical coherence Tomography and ultrasound. Skin Pharmacol Physiol 35(1):41–50

    Article  CAS  Google Scholar 

  10. Luger T, Paller AS, Irvine AD et al (2021) Topical therapy of atopic dermatitis with a focus on pimecrolimus. J Eur Acad Dermatol Venereol 35(7):1505–1518

    Article  CAS  Google Scholar 

  11. Asgari MM, Tsai AL, Avalos L et al (2020) Association between topical calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis. JAMA Dermatol 156(10):1066–1073

    Article  Google Scholar 

  12. Lübbe J, Friedlander SF, Cribier B et al (2006) Safety, efficacy, and dosage of 1 % pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol 7(2):121–131

    Article  Google Scholar 

  13. Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA (2016) Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. https://doi.org/10.1186/s12887-016-0607-9

    Article  PubMed  PubMed Central  Google Scholar 

  14. Luger T, Augustin M, Lambert J et al (2021) Unmet medical needs in the treatment of atopic dermatitis in infants: an expert consensus on safety and efficacy of pimecrolimus. Pediatr Allergy Immunol 32(3):414–424

    Article  Google Scholar 

  15. Bonamonte D, De Marco A, Giuffrida R et al (2020) Topical antibiotics in the dermatological clinical practice: Indications, efficacy, and adverse effects. Dermatol Ther 33(6):e13824

    Article  Google Scholar 

  16. Kreft B, Wohlrab J (2022) Contact allergies to topical antibiotic applications. Allergol Select 6:18–26

    Article  Google Scholar 

  17. Traidl S, Freimooser S, Werfel T (2021) Janus kinase inhibitors for the therapy of atopic dermatitis. Allergol Select 5:293–304

    Article  Google Scholar 

  18. Wohlrab J, Kreft B, Scholz LS (2021) Anti-inflammatory topical medication—new developments in the treatment of atopic dermatitis. Allergol Select 5:260–264

    Article  Google Scholar 

  19. European Medicines Agency (2021) new oral treatment for moderate to severe atopic dermatitis. https://www.ema.europa.eu/en/news/new-oral-treatment-moderate-severe-atopic-dermatitis (Updated 2020). Zugegriffen: 14. März 2022

  20. Lauffer F, Biedermann T (2022) Einschätzungen zur Therapie der moderat bis schweren atopischen Dermatitis mit Janus Kinase Inhibitoren. Hautarzt https://doi.org/10.1007/s00105-022-05004-6

    Article  PubMed  Google Scholar 

  21. Japan Tobacco Inc (2020) JT receives manufacturing and marketing approval ofCORECTIM® ointment 0.5%for the treatment of atopic dermatitis in Japan. https://www.jt.com/media/news/2020/pdf/20200123_E01.pdf. Zugegriffen: 9. Apr. 2021

  22. Papp K, Szepietowski JC, Kircik L et al (2021) Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol 85(4):863–872

    Article  CAS  Google Scholar 

  23. Bissonnette R, Papp KA, Poulin Y et al (2016) Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 175(5):902–911

    Article  CAS  Google Scholar 

  24. Nakagawa H, Nemoto O, Igarashi A et al (2020) Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol 82(4):823–831

    Article  CAS  Google Scholar 

  25. Piscitelli SC, Pavel AB, McHale K et al (2021) A phase 1b, randomized, single-center trial of topical cerdulatinib (DMVT-502) in patients with mild-to-moderate atopic dermatitis. J Invest Dermatol 141(7):1847–1851

    Article  CAS  Google Scholar 

  26. Paller AS, Tom WL, Lebwohl MG et al (2016) Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 75(3):494–503

    Article  CAS  Google Scholar 

  27. Saeki H et al (2022) Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial. Br J Dermatol 186(1):40–49

    Article  CAS  Google Scholar 

  28. Paller AS, Gold SL, Soung J et al (2021) Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. J Am Acad Dermatol 84(3):632–638

    Article  CAS  Google Scholar 

  29. Oetjen LK, Mach MR, Feng J et al (2017) Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell 171:217–228

    Article  CAS  Google Scholar 

  30. Nakagawa H, Nemoto O, Igarashi A et al (2020) Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol 47(2):114–120

    Article  CAS  Google Scholar 

  31. Gong X, Chen X, Kuligowski ME et al (2021) Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: data from phase II and III studies. Am J Clin Dermatol 22(4):555–566

    Article  Google Scholar 

  32. Hanifin JM, Ellis C, Frieden I et al (2016) OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase‑4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 75(2):297–305

    Article  CAS  Google Scholar 

  33. Saeki H, Kawashima M, Sugaya S et al (2019) Efficacy and safety of topical OPA-15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized, double-blind, placebo-controlled study. J Dermatol 46(8):672–679

    Article  CAS  Google Scholar 

  34. Hu YQ, Liu P, Mu Z et al (2020) Aryl hydrocarbon receptor expression in serum, peripheral blood mononuclear cells, and skin lesions of patients with atopic dermatitis and its correlation with disease severity. Chung Hua I Hsueh Tsa Chih 133(2):148–153

    Google Scholar 

  35. Hwang J, Newton EM, Hsiao J, Shi VY (2022) Aryl hydrocarbon receptor/nuclear factor E2-related factor 2 (AHR/NRF2) signaling: a novel therapeutic target for atopic dermatitis. Exp Dermatol. https://doi.org/10.1111/exd.14541

    Article  PubMed  Google Scholar 

  36. Merk HF (2019) Aryl-Hydrocarbon-Rezeptor als Zielstruktur für neue Medikamente bei Psoriasis und atopischer Dermatitis. Hautarzt 70(12):942–947

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Sina Freimooser, Stephan Traidl & Thomas Werfel

Authors
  1. Sina Freimooser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephan Traidl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Werfel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sina Freimooser.

Ethics declarations

Interessenkonflikt

S. Traidl deklariert Beratungstätigkeiten für Leo Pharma, La Roche-Posay und Lilly. T. Werfel ist Co-Principal Investigator des deutschen Registers für atopische Dermatitis TREATgermany; er erhielt Honorare für Vorträge und Beratungstätigkeiten für AbbVie, Almirall, Galderma, Janssen/JNJ, Leo Pharma, Leti, Lilly, Novartis, Pfizer und Regeneron/Sanofi. S. Freimooser gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Freimooser, S., Traidl, S. & Werfel, T. Entwicklung von neuen topischen Substanzen zur Therapie der atopischen Dermatitis. Dermatologie 73, 514–519 (2022). https://doi.org/10.1007/s00105-022-05005-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-022-05005-5

Schlüsselwörter

Keywords

Search

Navigation